Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest STAT3 Stories

2014-01-07 13:48:44

Inhibitors of both JAK and Src kinases represent promising targets for cancer therapeutics because of the central importance of these kinases in tumor cell proliferation and survival. Furthermore, in cancer cells activation of JAK has been reported as a compensatory effect in response to Src inhibitor exposure. This implies simultaneous inhibition of both kinases could have a synergy of anti-cancer effects compared to an agent that inhibits one or the other kinases. The research article by...

2013-06-03 16:26:27

Data presented today at the American Society of Clinical Oncology CARLSBAD, Calif., June 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3(Rx) in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago. Results of the initial dose escalation study in patients with metastatic cancer showed that ISIS-STAT3(Rx) treatment resulted in partial responses that were...

2012-12-11 08:26:40

CARLSBAD, Calif., Dec. 11, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca announced today a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialise ISIS-STAT3(Rx), a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas. Antisense therapies target the proteins involved in disease processes by...

2012-10-31 07:28:09

CARLSBAD, Calif., Oct. 31, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that preliminary data from the Phase 1 study of ISIS-STAT3(Rx) in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston. Interim results of the initial dose escalation study in patients with cancer showed that ISIS-STAT3(Rx) treatment resulted in clear responses in patients with advanced cancer who were refractory to prior chemotherapy treatment, with...

2012-07-13 10:38:25

An important breakthrough by IRCM researchers contributes to a better understanding of the human genome Researchers at the IRCM, led by geneticist Dr. Jacques Drouin, recently defined the interaction between two essential proteins that control inflammation. This important breakthrough will be published in tomorrow's print edition of the scientific journal Molecular Cell. IRCM scientists study glucocorticoids, a class of steroid hormones that suppress the immune system and reduce...

2012-05-17 09:59:17

Implications in the pathogenesis of autoimmune diseases LGL leukemia is a relatively rare, malignant blood disease of the mature T-cells and, in many cases, it is related to autoimmune diseases such as rheumatoid arthritis. The pathogenetic mechanism of the disease has been unknown and it has previously been unclear if the disease is an overreaction of the normal defense system or a malignant hematological disease. One of the key symptoms of LGL disease is a low count of white blood...

2012-03-07 07:00:00

CARLSBAD, Calif., March 7, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug designed to treat cancer. ISIS-STAT3Rx specifically reduces the production of signal transducer and activator of transcription 3 (STAT3). Because STAT3 is over expressed in numerous types of cancers, ISIS-STAT3Rx has the potential to be broadly useful for both solid and liquid tumors. The ISIS-STAT3Rx...

2012-02-09 23:47:12

Researchers at Moffitt Cancer Center in Tampa, Fla., have discovered that the immune response regulator IKBKE (serine/threonine kinase) plays two roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens induce IKBKE and, in turn, IKBKE induces chemotherapy resistance. "IKBKE is a newly identified oconogene, a gene linked to cancer," said study lead author Jin Q. Cheng, Ph.D., M.D., who studies genetic alterations and their molecular mechanisms in cancer. "In our study, we...

2012-02-02 18:00:48

TGen-VARI study of protein JAK2 published by Public Library of Science Combination drug therapy may be needed to combat non-small cell lung cancer (NSCLC), according to a study by the Translational Genomics Research Institute (TGen) and Van Andel Research Institute (VARI). The study, "STAT3 is Activated by JAK2 Independent of Key Oncogenic Driver Mutation in Non-Small Cell Lung Carcinoma," was published online today, Feb. 2, 2012, by the Public Library of Science (PLoS) ONE. The...

2012-01-26 10:05:23

Ovarian cancer is a major cause of death worldwide. Approximately 25,000 women will be diagnosed with ovarian cancer this year and 15,000 women will die from it in the United States alone. The novel anti-cancer drug diindolylmethane (DIM) has been shown in laboratory to inhibit the growth of ovarian cancer cells. New research published in BioMed Central's open access journal BMC Medicine has looked in detail at the action of DIM and showed that it works by blocking the activation and...